<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25443189</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Bañeros-Rojas, P</dc:author>
<dc:author>Díaz-Valle, D</dc:author>
<dc:author>Peraza-Nieves, J E</dc:author>
<dc:author>Berrozpe-Villabona, C</dc:author>
<dc:description xml:lang="en">CASE REPORT A 24 year old woman who complained of maculo-papulo rash, genital and bucal aphthous ulcers, abdominal pain, minor dyspnea and visual loss in both eyes. Funduscopy revealed a bilateral occlusive vasculitis including central vessels. Treatment was initiated with a methylprednisolone bolus (1 g/24h) and infliximab 5mg/kg/day (0-2-6 weeks and every 8 weeks). The treatment prescribed induced a fast remission. Visual acuity improved. The patient did not suffer any other relapse after one year of follow-up. DISCUSSION An initial treatment with Infliximab should be considered in Behçet disease for serious outbreaks, such as macular occlusive vasculitis with ischemia.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:subject>Behçet disease</dc:subject>
<dc:subject>Infliximab</dc:subject>
<dc:subject>TNF-α</dc:subject>
<dc:subject>Retinal vasculitis</dc:subject>
<dc:subject>Vasculitis retiniana</dc:subject>
<dc:subject>Uveitis</dc:subject>
<dc:subject>Enfermedad de Behçet</dc:subject>
<dc:subject>Uveítis</dc:subject>
<dc:date>2015 Jun </dc:date>
<dc:title xml:lang="en">Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Behçet' disease.</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
